Vivek Subbiah, Director of Early Phase Drug Development Program at NYU Langone Health, shared on LinkedIn:
“Wearing purple tie for Pancreatic Cancer Awareness Day.
A landmark year: the first RAS-targeted therapy approved for pancreatic cancer. Still far to go- but eager to work across all stakeholder groups to tackle this beast, with our novel agents including 100+ KRAS-targeted therapies in different stages of research + we need RAS inhibitors approved in a tissue-agnostic manner across all cancers.
Thanks, Simon C, for making me wear a purple tie and arranging a big celebration in New York!”

You may also be interested in: